Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSecond Affiliated Hospital of Guangzhou Medical University
About this trial
This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
Eligibility criteria
Qualifiers
Unresectable HCC (BCLC stage B/C or CNLC II/III) with diagnosis confirmed by histology/cytology or clinically
At least one measurable untreated lesion
Intrahepatic tumors can be treated with 1-2 sessions of SIRT
Child-Pugh score 5-7
Disqualifiers
tumor extent ≥70% liver occupation
Tumor thrombus involving main portal vein or both the first left and right branches of portal vein
Vena cava invasion
Central nervous system metastasis
Trial design
Treatments tested in this trial
- Sin-Bev-SIRT
Treatment groups
23 Participants
are divided into 1 treatment groupLocations
1the Second Affiliated Hospital of Guangzhou Medical University510260, GuangzhouGuangdong, China
Sponsors and collaborators
Second Affiliated Hospital of Guangzhou Medical University
Lead sponsor
Source ClinicalTrials.gov